Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 280

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Performance and Safety of a New Ab Interno Gelatin Stent in Refractory Glaucoma at 12 Months

Open access
Grover, Davinder S., Flynn, William J., Bashford, Kent P., Lewis, Richard A., Duh, Yi-Jing, Nangia, Rupali S., Niksch, Barbara·2017·American Journal of Ophthalmology

Abstract

PURPOSE: To evaluate the intraocular pressure (IOP)-lowering performance and safety of an ab interno gelatin stent (XEN 45 Gel Stent, Allergan plc, Irvine, California, USA), a minimally invasive glaucoma surgery device, in refractory glaucoma. DESIGN: Single-arm, open-label, multicenter clinical study. METHODS: Following mitomycin C pretreatment, the stent was placed ab interno in patients who failed prior filtering/cilioablative procedure or had uncontrolled IOP on maximum-tolerated medical therapy, with medicated IOP ≥20 and ≤35 mm Hg and visual field mean deviation ≤-3 dB. Primary performance outcomes: patients (%) achieving ≥20% IOP reduction from baseline on the same or fewer medications and mean IOP change from baseline at month 12. Procedure-related complications and ocular adverse events (AEs) were assessed. RESULTS: Sixty-five patients were implanted (intent-to-treat/safety population). At 12 months, 75.4% (46/61; observed data) reported ≥20% IOP lowering from baseline on the same or fewer medications. Mean IOP change from baseline was -9.1 mm Hg (95% confidence interval [CI]: -10.7, -7.5) (n = 52; observed data) at 12 months, excluding patients with missing data (n = 4) and those requiring a glaucoma-related secondary surgical intervention (n = 9). Mean medication count decreased from 3.5 (baseline) to 1.7 (12 months). No intraoperative complications or unexpected postoperative AEs were reported. Most AEs were mild/moderate; common AEs included needling (without sight-threatening complications), nonpersistent loss of best-corrected visual acuity, and transient hypotony (requiring no surgical intervention). CONCLUSIONS: The gelatin stent reduced IOP and medication use without raising unexpected safety concerns, offering a minimally invasive surgical option for refractory glaucoma patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajo.2017.07.023

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 280

Metadata

Authors
Grover, D. S., Flynn, W. J., Bashford, K. P., Lewis, R. A., Duh, Y.-J., Nangia, R. S., & Niksch, B.
Venue
American Journal of Ophthalmology
Publisher
Elsevier BV
Published
2017-11
Volume
183
Pages
25-36
ISSN
0002-9394 (ISSN-L)
OpenAlex
W2745069984
Cited by
280
References
1
FWCI
27.64
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Performance and Safety of a New Ab Interno Gelatin Stent in Refractory Glaucoma at 12 Months. https://app.cochat.ai/papers/10.1016/j.ajo.2017.07.023
The paper
Grover, D. S., Flynn, W. J., Bashford, K. P., Lewis, R. A., Duh, Y.-J., Nangia, R. S., & Niksch, B. (2017). Performance and Safety of a New Ab Interno Gelatin Stent in Refractory Glaucoma at 12 Months. American Journal of Ophthalmology. https://doi.org/10.1016/j.ajo.2017.07.023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.